Search
News Archive
Categories
Health Enhancement Products, Inc. Expands Intellectual Property Development Effort With Preeminent Research Scientist and Patent Counsel
Posted On: April 13, 2012Arizona-based algae producer Health Enhancement Products (OTCBB: HEPI) has engaged preeminent research scientist Dr. William Gerwick, Distinguished Professor of Oceanography and Pharmaceutical Sciences at the Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences located in the La Jolla campus of the University of California at San Diego.
Dr. Gerwick’s current research focuses on the discovery of bioactive molecules with potential anticancer, antibacterial, neurotoxic, antiviral, or anti-inflammatory activity from marine organisms, such as algae. The pathways by which these complex molecules are assembled form the basis of Dr. Gerwick’s research, using stable isotope tracer methods and NMR analysis. Many marine algae produce prostaglandin and leukotriene analogs that are strikingly similar to substances produced in the human body, and that have therapeutic value as potential pharmacological agents.
OECD Conference on Marine Biotechnology for Ocean Productivity and Sustainability: May 30-31 2012
Posted On: March 23, 2012This conference, held in late May in Vancouver, Canada, will address opportunities for marine biotechnology to contribute to global challenges such as of food and fuel security, population health, green growth and sustainable industries. The event aims at raising awareness among policy makers of the potential of the marine environment and how this potential could be realized through the use of marine biotechnology, in particular in the areas of generating economic benefit and environmental sustainability.
Marine Drugs Announces New Issue: Mar. Drugs, Volume 10, Issue 3
Posted On: March 23, 2012MDPI recently announced the publication of the following issue:
Mar. Drugs, Volume 10, Issue 3 (March 2012), Pages Pages 521-676
http://www.mdpi.com/1660-3397/10/3/
Table of Contents:
Jing Tong, Hank Trapido-Rosenthal, Jun Wang, Youwei Wang, Qing X. Li and Yuanan Lu
Article: Antiviral Activities and Putative Identification of Compounds in Microbial Extracts from the Hawaiian Coastal Waters
Mar. Drugs 2012, 10(3), 521-538; doi:10.3390/md10030521
http://www.mdpi.com/1660-3397/10/3/521/
Li Sun, Dongli Li, Meihua Tao, Yuchan Chen, Feijun Dan and Weimin Zhang
Article: Scopararanes C–G: New Oxygenated Pimarane Diterpenes from the Marine Sediment-Derived Fungus Eutypella scoparia FS26
Mar. Drugs 2012, 10(3), 539-550; doi:10.3390/md10030539
http://www.mdpi.com/1660-3397/10/3/539/
Zeping Xie, Bing Liu, Hongpeng Wang, Shengxiang Yang, Hongyu Zhang, Yipeng Wang, Naiyun Ji, Song Qin and Hartmut Laatsch
Article: Kiamycin, a Unique Cytotoxic Angucyclinone Derivative from a Marine Streptomyces sp.
Mar. Drugs 2012, 10(3), 551-558; doi:10.3390/md10030551
http://www.mdpi.com/1660-3397/10/3/551/
Yun-Jing Chai, Cheng-Bin Cui, Chang-Wei Li, Chang-Jing Wu, Cong-Kui Tian and Wei Hua
Article: Activation of the Dormant Secondary Metabolite Production by Introducing Gentamicin-Resistance in a Marine-Derived Penicillium purpurogenum G59
Mar. Drugs 2012, 10(3), 559-582; doi:10.3390/md10030559
http://www.mdpi.com/1660-3397/10/3/559/
Danielle F. Mello, Eliza S. de Oliveira, Renato C. Vieira, Erik Simoes, Rafael Trevisan, Alcir Luiz Dafre and Margherita Anna Barracco
Article: Cellular and Transcriptional Responses of Crassostrea gigas Hemocytes Exposed in Vitro to Brevetoxin (PbTx-2)
Mar. Drugs 2012, 10(3), 583-597; doi:10.3390/md10030583
http://www.mdpi.com/1660-3397/10/3/583/
Yan-Bo Zeng, Hui Wang, Wen-Jian Zuo, Bo Zheng, Tao Yang, Hao-Fu Dai and Wen-Li Mei
Article: A Fatty Acid Glycoside from a Marine-Derived Fungus Isolated from Mangrove PlantScyphiphora hydrophyllacea
Mar. Drugs 2012, 10(3), 598-603; doi:10.3390/md10030598
http://www.mdpi.com/1660-3397/10/3/598/
Nicolantonio D’Orazio, Eugenio Gemello, Maria Gammone, Massimo de Girolamo, Cristiana Ficoneri and Graziano Riccioni
Review: Fucoxantin: A Treasure from the Sea
Mar. Drugs 2012, 10(3), 604-616; doi:10.3390/md10030604
http://www.mdpi.com/1660-3397/10/3/604/
Wan-Yu Lin, Yi Lu, Bo-Wei Chen, Chiung-Yao Huang, Jui-Hsin Su, Zhi-Hong Wen, Chang-Feng Dai, Yao-Haur Kuo and Jyh-Horng Sheu
Article: Sarcocrassocolides M–O, Bioactive Cembranoids from the Dongsha Atoll Soft CoralSarcophyton crassocaule
Mar. Drugs 2012, 10(3), 617-626; doi:10.3390/md10030617
http://www.mdpi.com/1660-3397/10/3/617/
Hou-Jin Li, Ying-Lu Xie, Zhong-Liang Xie, Ying Chen, Chi-Keung Lam and Wen-Jian Lan
Article: Chondrosterins A–E, Triquinane-Type Sesquiterpenoids from Soft Coral-Associated FungusChondrostereum sp.
Mar. Drugs 2012, 10(3), 627-638; doi:10.3390/md10030627
http://www.mdpi.com/1660-3397/10/3/627/
Min-Juan Xu, Xiao-Jin Liu, Yi-Lei Zhao, Dong Liu, Zhen-Hao Xu, Xiao-Meng Lang, Ping Ao, Wen-Han Lin, Song-Lin Yang, Zhi-Gang Zhang and Jun Xu
Article: Identification and Characterization of an Anti-Fibrotic Benzopyran Compound Isolated from Mangrove-Derived Streptomyces xiamenensis
Mar. Drugs 2012, 10(3), 639-654; doi:10.3390/md10030639
http://www.mdpi.com/1660-3397/10/3/639/
Yuta Kudo, Takeshi Yasumoto, Keiichi Konoki, Yuko Cho and Mari Yotsu-Yamashita
Article: Isolation and Structural Determination of the First 8-epi-type Tetrodotoxin Analogs from the Newt, Cynops ensicauda popei, and Comparison of Tetrodotoxin Analogs Profiles of This Newt and the Puffer Fish, Fugu poecilonotus
Mar. Drugs 2012, 10(3), 655-667; doi:10.3390/md10030655
http://www.mdpi.com/1660-3397/10/3/655/
Zhuang Han, Ying Xu, Oliver McConnell, Lingli Liu, Yongxin Li, Shuhua Qi, Xiangzhong Huang and Peiyuan Qian
Article: Two Antimycin A Analogues from Marine-Derived Actinomycete Streptomyces lusitanus
Mar. Drugs 2012, 10(3), 668-676; doi:10.3390/md10030668
http://www.mdpi.com/1660-3397/10/3/668/
Scots and Aussie scientists team up to research marine microbes
Posted On: March 12, 2012A leading Scottish marine biotechnology firm has joined forces with the Australian Institute of Marine Science (AIMS) in a bid to discover innovative and high-value products from micro-organisms.
Scientists from Aquapharm Biotechnology are to be given exclusive commercial access to a selection of Australian marine microbes in the AIMS Bioresources Library.
Aquapharm believes the deal will lead to the discovery of useful new active ingredients for use in pharmaceutical, nutritional and personal care products.
Jon Williams, VP Commercial at Aquapharm, explained: “AIMS is amongst the world’s top specialist research institutions, and it has cultivated a sizeable collection of marine micro-organisms from Australia’s unique marine territory. This territory spans an immense 16 million square kilometres, leading to high biodiversity and the potential for novel microbes and their products.
“Aquapharm has signed an agreement with AIMS that grants us exclusive commercial access to a select range of these organisms for testing and development, with the option to conclude an exclusive licence agreement for commercialization if they are found to be suitable.
Aqua Bio Technology Signs Milestone Sales Agreement for Marine-Derived Ingredient
Posted On: March 3, 2012Aqua Bio Technology ASA (Oslo Axess: ABT) today announced a partnership with Amway, one of the world’s largest direct sellers, for the use of ABT’s lead marine-derived ingredient Aquabeautine XL® in ARTISTRY® skincare products. ABT expects the agreement to provide revenues of at least NOK 8 million over the next 30 months, with a significant upside potential.
“The agreement with Amway is our most important commercial milestone to date. It confirms the potential of Aquabeautine XL® as a key component in the next generation of skincare products. Furthermore, our relationship with Amway will serve as an important reference as we roll out our new marketing strategy,” said ABT’s CEO Arvid Lindberg.
Michigan, US-based Amway is a worldwide leader in direct selling, with more than three million Independent Business Owners (IBOs) in more than 80 countries and territories around the world. Its ARTISTRY® is among the world’s top five, largest-selling, premium skincare brands.
Sapphire to License Earthrise Spirulina for Green Crude
Posted On: March 2, 2012Sapphire Energy has announced it has entered into a licensing agreement with Earthrise Nutritionals LLC, Southern California-based producer of spirulina and spirulina-based products, to integrate Earthrise’s spirulina strain into Sapphire’s growing inventory of cyanobacteria and algae strains for algae-to-energy production. As a result of this agreement, Sapphire significantly improves its operational efficiency by expanding the range of strain choices available for producing Sapphire Energy’s Green Crude – a drop-in replacement for petroleum-based crude oil – that can be refined into diesel, jet fuel, and gasoline.
Newcastle University scientists work on using marine bacteria to produce electricity
Posted On: February 22, 2012How to find and exploit new sources of energy for our power-hungry society is something which has been bugging experts for decades.
Now scientists at Newcastle University are working on how to harness bacteria to produce electricity.
And some of the microbes in the study are Bacillus stratosphericus – commonly found in high concentrations in the stratosphere orbiting the Earth with the satellites.
They are a key component of a bacteria “designer” slime which has been created at the university.
The scientists tested each of 75 bacteria species found in sediment from the estuary of the River Wear – including the space bugs which were also discovered to be present in the sample.
Their aim was to select the top 10 electricity-producing bacteria and allow them to grow and colonise an electrode. The experiment involving a microbial fuel cell (MFC) resulted in a doubling of electrical output by using the best-performing bugs.
The study is being led by Professor Keith Scott, of the university’s School of Chemical Engineering and Advanced Materials, and Grant Burgess, Professor of Marine Biotechnology.
Lasya, Inc. Announces Strategic Partnership with Maxey Cosmetics
Posted On: February 20, 2012Lasya, Incorporated has entered into a strategic partnership with Maxey Cosmetics, makers of the advanced cosmetic eyeliner Maxeylash Maintenance, with operations in Estonia and the Czech Republic. This partnership will facilitate a global distribution of Lanterna, the cosmetic alternative to hydroquinone-containing products. Lanterna contains deoxyArbutin, shown to be ten times more effective and significantly safer than its prescription counterpart.
Maxeylash Maintenance is a unique lash conditioner, designed to protect and condition eyelashes and enhance their appearance. Maxeylash Maintenance is formulated with Black Sea Rod Oil, a natural marine extract and innovative alternative to the prescription drugs used on lashes in the past.
Algae.Tec Successfully Completes $5m Capital Raising With Patersons Securities
Posted On: February 3, 2012Algae.Tec Ltd has announced that the AUD$5,000,000 (USD$5,354,086.97) Placement through Patersons Securities Limited has been successfully completed.
As previously stated, this capital raising will be utilised to fund the fast-tracking of commercial projects recently announced.
Algae.Tec Executive Chairman, Roger Stroud, said the Company was extremely pleased with the capital raising.
“This again demonstrates that sophisticated investors are aligned with the need for alternative transport fuel technologies such as the Algae.Tec enclosed algae to biofuels solution,” said Stroud.
“The market is also responding to the recent milestones and commercial deal announcements the Company has signed with major companies in China, Sri Lanka and Europe.”
Scots and Nordic scientists set to explore sustainable skincare utilizing marine natural ingredients
Posted On: January 30, 2012Scottish company Aquapharm has joined forces with Norwegian firm Aqua Bio Technology (ABT) to create a new generation of sustainable ingredients for the skincare market.
Together the companies hope to identify natural marine ingredients that could replace the petroleum-based components used extensively within the skincare market.
Scientists at Aquapharm believe marine microbes are the key to finding the bio-active ingredients of the future, and have developed specialist fermentation processes to source and produce such extracts.
Now they will undertake a development program in conjunction with ABT, sharing their expertise in a bid to prove these extracts can be produced with minimal environmental impact – and successfully commercialized for the personal care market.
Host
 |
Partners
  |
Sponsors
 |
 |
Share Aquapreneur
